Clinical Trial Initiation: The company is progressing towards starting a Phase II clinical trial for NV-387 as a treatment for Monkeypox in the Democratic Republic of Congo, with local regulatory approval already obtained.
Monkeypox Epidemic Status: The Africa CDC has declared a "Public Health Emergency of Continental Security" due to the ongoing Monkeypox epidemic, driven by more virulent strains, Clade 1a and 1b, which have higher fatality rates compared to the less virulent Clade 2.
Regulatory Strategy: The company aims to leverage data from international clinical trials to advance NV-387's regulatory status with the US FDA, targeting orphan drug designations for multiple diseases including Monkeypox, Smallpox, and Measles.
Benefits of Orphan Drug Designation: If granted, the Orphan Drug Designation for NV-387 would provide advantages such as expedited FDA meetings, tax credits for R&D, fee waivers, and seven years of market exclusivity for the approved indications.
Wall Street analysts forecast NNVC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNVC is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NNVC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNVC is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.150
Low
6.00
Averages
6.00
High
6.00
Current: 1.150
Low
6.00
Averages
6.00
High
6.00
Alliance Global
James Molloy
initiated
$6
2025-12-16
Reason
Alliance Global
James Molloy
Price Target
$6
AI Analysis
2025-12-16
initiated
Reason
Alliance Global analyst James Molloy initiated coverage of NanoViricides with a Buy rating and $6 price target. NanoViricides is a nano-pharmaceutical company that specializes in creating novel treatments for viral infections, the analyst tells investors in a research note. The firm believes the opportunity for the company "could be significant" should NV-387 show positive data in the planned Phase 2 trials.
About NNVC
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
